Antibiotics can effectively prevent intestinal cancer metastasis

Share This Post

Researchers from Harvard University found evidence in a new study that colon cancer cells carry certain bacteria when they metastasize to other organs in the body. The results of the study were published in the journal Science, and the team described their possible association with bacteria and their cause of colon cancer.

Previous research has shown that bacteria and tumor cells are present in various types of cancer, which makes some people in the medical community wonder whether they are the real cause of tumor formation. A bacterium called Fusobacterium nucleatum has been shown to exist in colon cancer cells. In this new study, the researchers wanted to know whether the same bacteria can be found in colon cancer tumor cells when these cancer cells have metastasized to other parts of the body.

To find out, the researchers collected tissue samples from patients with colon cancerIn the course of the research, they found that in many cases, the same bacterial strain exists in the tumor. Even if colon cancer cells have metastasized, the most common metastatic site of colon cancer is the liver, but there is no evidence to show that the bacteria in colon cancer cells , Present in the liver.

The researchers were very interested in this discovery. The researchers implanted tumors in healthy mice, so they found that those tumors with bacteria began to grow. Next, the research team tested the possibility of using antibiotics capable of killing F. nucleatum to treat colon cancer mice. They found that doing so actually slowed the growth of the tumor.

This discovery allows researchers to find a new direction against colon cancer, and hopes that further research can prove the effectiveness and safety of this method. 

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy